Biotechnology company Can-Fite BioPharma has obtained approval from the Institutional Review Board (IRB) of Barzilai Medical Center in Israel, to begin patient enrolment in the Phase III ACRobat clinical trial of piclidenoson for the treatment of rheumatoid arthritis.

Can-Fite also expects to receive IRB approvals from medical centres in Canada and Europe.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Piclidenoson is an orally bioavailable, small molecule agonist of A3 adenosine receptor (A3AR) being developed as a first-line replacement therapy for the existing standard-of-care drug methotrexate (MTX).

Expected to enrol a total of up to 500 patients in Israel, Europe and Canada, the randomised, double-blind, active and placebo-controlled Phase III trial will evaluate 1mg and 2mg of piclidenoson twice-daily over a period of 24 weeks.

"Can-Fite also expects to receive IRB approvals from medical centres in Canada and Europe."

The trial will also include a once-weekly administration of MTX.

The primary endpoint of the trial is low disease activity following 12 weeks of treatment in comparison to MTX.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Can-Fite chief executive officer Dr Pnina Fishman said: "Piclidenoson has demonstrated its safety profile in over 1,000 patients and prior clinical data show its potential to be as effective, or more effective, than MTX in treating rheumatoid arthritis.

"Our ACRobat trial is powered to demonstrate piclidenoson's potential as a first line therapy and superior alternative to MTX, which unfortunately can have severe side effects for patients who need a long-term treatment solution."

Piclidenoson is also being evaluated in another Phase III clinical trial for the treatment of psoriasis and is reported to have shown favourable therapeutic index in Phase II trials.